Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE
July 2011
REPORT TYPE
Annual Summary
DATES COVERED
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERVanderbilt University Nashville, TN 37232
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACTPTEN is lost in a significant percentage of prostate cancers, which has been verified in animal models. However, these models fail to assess the role of PTEN in development given the usage of promoters regulated at differentiation. Results generated by knocking down PTEN in a human model of normal prostatic regeneration show both an arrested differentiation identified with progenitor cell markers and transdifferentiation to various urogenital organs including bladder, urethra and intestine. Each organ type is surrounded by representative differentiated stroma suggesting that gradients of PTEN expression may dictate the development of various urogenital organs. Stromal changes have also been associated with disease progression, which is difficult to model in transgenic animals due to the lack of appropriate promoters. To overcome this limitation, a human prostate fibroblast cell line has been generated along with a number of derivatives ectopically expressing chemokines and cytokines of 4 Introduction Benign prostatic hyperplasia (BPH) is an enlargement of the transitional and periurethral area of the prostate gland that affects 60% of men over 60 years old. 50% of men at age 50 have lower urinary tract symptoms (LUTS) arising from BPH and 20-30% require surgical intervention by age 80. The etiology of BPH is still unknown although analyses of comorbities and retrospective studies of patients on medications for comorbidities have revealed insights into potential molecular mechanisms. The current treatment regimen for BPH is initially to place patients on uroselective (alfuzosin SR, tamsulosin) or nonuroselect...